<DOC>
	<DOC>NCT01256671</DOC>
	<brief_summary>The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.</brief_summary>
	<brief_title>DHEA Against Vaginal Atrophy - Safety Study of 12 Months</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Main Postmenopausal women (nonhysterectomized) Women between 40 and 75 years of age. Willing to participate in the study and sign an informed consent. Women who have selfidentified symptom(s) of vaginal atrophy. Willing to have endometrial biopsy at screening and end of study (Week 52). Main Undiagnosed abnormal genital bleeding. Hypertension equal to or above 140/90 mm Hg. The administration of any investigational drug within 30 days of screening visit. Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vulvar/Vaginal Atrophy</keyword>
	<keyword>Atrophic Vaginitis</keyword>
	<keyword>Dehydroepiandrosterone</keyword>
	<keyword>DHEA</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Vaginorm</keyword>
	<keyword>Menopause</keyword>
</DOC>